Exhibit 10.1
***Text Omitted and Filed Separately with the Securities and
Exchange Commission. Confidential Treatment Requested
Under 17. C.F.R. Sections 200.80(b)(4) and 240.24b-2.
THIRD AMENDMENT TO
COLLABORATIVE RESEARCH, DEVELOPMENT
AND LICENSE AGREEMENTS
T HIS T HIRD A MENDMENT TO C OLLABORATIVE R ESEARCH , D EVELOPMENT AND L ICENSE A GREEMENTS (the “Third
Amendment ” ) is entered into as of March 3, 2008 (the “Third Amendment Effective Date” ) by and between ACADIA P
HARMACEUTICALS I NC . , a Delaware corporation ( “ACADIA ” ) with offices at 3911 Sorrento Valley Blvd., San Diego, CA
92121, and A LLERGAN S ALES , LLC , a Delaware limited liability company ( “Allergan ” ) with offices at 2525 Dupont Drive,
Irvine, CA 92612, and A LLERGAN , I NC . , a Delaware corporation, solely as guarantor of the performance under this Agreement
by Allergan.
R ECITALS
W HEREAS , the parties previously entered into that certain Collaborative Research, Development and License Agreement,
dated September 24, 1997 (as amended by the First Amendment and the Second Amendment described below, the “1997
Agreement ” ), pursuant to which the parties conducted collaborative research regarding, among other things, receptor selective
compounds with the goal of establishing drug discovery programs related to such receptor selective compounds;
W HEREAS , the parties previously entered into that certain Collaborative Research, Development and License Agreement,
dated July 26, 1999 (the “1999 Agreement” ), pursuant to which the parties conducted collaborative research regarding […
***…] muscarinic compounds for the treatment or prevention of ocular disease.
W HEREAS , the 1997 Agreement was first amended on March 27, 2003 (the “ First Amendment” ) to continue the
collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered
into a new Collaborative Research, Development and License Agreement (the “2003 Agreement” ) regarding ACADIA’s
chemical-geno